CanadaApo‑Semaglutide Injection (Apo‑Semaglutide 4 mg/pen, DIN 02568012, strength 1.34 mg/mL, lot 7000636A) sold by Apotex Inc. in several Canadian provinces is affected; the dose window may display 0.25 mg or 0.5 mg even though a 1 mg dose is expected. The product was recalled because it may deliver 0.25 mg or 0.5 mg instead of 1 mg; verify if your product is affected, consult your healthcare provider before stopping use, contact Apotex with questions, and report any side effects or safety complaints to Health Canada.
What's being recalled
Depth of Recall: Retailers
Companies: Apotex Inc., 150 Signet Drive,, Toronto, ON, M9L 1T9.
How to identify it
Brand: Apotex Inc.; Product Name: Apo-Semaglutide (4mg/pen); Market Authorization: DIN 02568012; Dosage Form: Solution; Strength: 1.34 mg/mL; Lot Number: 7000636A
The hazard
The affected lot may display a dose of 0.25 mg or 0.5 mg in the dose window and deliver one of these doses instead of the expected 1 mg dose.
What to do
Verify if your product is affected.
Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.
Contact the recalling firm if you have any questions about the recall.
Report any health product related side effects to Health Canada.
Report any other health product safety complaints to Health Canada.
Where it was sold
Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Ontario, Quebec
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)